Comparative Pharmacology
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MOXAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MOXAM.
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs MOXAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
500 mg or 750 mg intravenously once daily. Infusion over 60-90 minutes.
400 mg orally every 24 hours for 7-14 days.
None Documented
None Documented
6-8 hours in patients with normal renal function (creatinine clearance >50 mL/min); increases to 20-48 hours in severe renal impairment (CrCl <20 mL/min); clinically relevant for dosing interval adjustment.
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
Renal: ~87% of dose excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5% eliminated as unchanged drug and metabolites; <4% recovered in feces.
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic